Clinicopathologic Characteristics, Treatment Outcomes of Pediatric Mycosis Fungoides in Turkey: A National Multicenter Retrospective Cohort
Pediatric Dermatology, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1111/pde.70349
- Dergi Adı: Pediatric Dermatology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
- Anahtar Kelimeler: adolescent, child, cutaneous t-cell lymphoma, mycosis fungoides, phototherapy, prognosis, recurrence, treatment outcome
- Kocaeli Üniversitesi Adresli: Evet
Özet
Background and Objectives: This study aimed to characterize the clinical spectrum, diagnostic delay, treatment patterns, and outcomes of pediatric mycosis fungoides (MF) and to identify predictors of early response. Methods: This national multicenter retrospective study included patients diagnosed with histopathologically confirmed MF before 18 years of age. Demographic, clinical, histopathologic, immunophenotypic, staging, treatment, and follow-up data were collected. Early response at 3–6 months (partial/complete response) was analyzed using logistic regression. Results: A total of 133 patients were included; 60.9% (81/133) were male. Median age at diagnosis was 13 years (IQR, 9–15) and median diagnostic delay was 18 months (IQR, 8–48). Classic morphology was recorded in 78.2% (104/133), and hypopigmented MF in 36.1% (48/133); overlapping morphologies were documented in 42.1% (56/133). Stage IA disease was present in 59.4% (79/133). Phototherapy was used in 60.9% (81/133). Early response occurred in 91.0% (121/133). BSA < 10% was independently associated with higher odds of early response (aOR 8.42, 95% CI 1.71–41.54; p = 0.009), whereas older age at diagnosis predicted lower odds (aOR 0.81 per year, 95% CI 0.67–0.98; p = 0.029). Relapse occurred in 28.5% (37/130) within median follow-up of 22 months (median time to relapse of 8 months); 67.6% (25/37) relapsed within 12 months. Conclusion: In this cohort, pediatric MF presented at an early stage. Despite favorable early responses, relapse occurred in nearly one third, often within the first year, supporting long-term surveillance. Higher BSA involvement and older age at diagnosis were associated with reduced early response.